Emerging biomarkers, such as secretoneurin, sST2, or heart-type fatty acid-binding protein (H-FABP), appear more tightly linked to mechanisms specific to SCM, including myocardial strain, endothelial dysfunction, and innate immune activation [47, 48, 50–56, 69, 70]. The gene discussed is SCG2; the disease is endothelial dysfunction.